A South Korean erectile dysfunction pill could become the first U.S. drug approved to slow Alzheimer’s disease, The Washington Post reported. Researchers said a lower‑dose version of the drug, sold as Mvix, slowed cognitive decline in a year‑long trial of more than 1,500 early‑stage patients.
First oral pill to slow Alzheimer’s could hit U.S. market
The experimental compound, AR1001, reduced decline by about 31% among the 40% of participants not taking other dementia medications, while those on concurrent therapies showed little benefit. Decline was measured through caregiver interviews and patient assessments of memory, judgment and daily functioning.
Overall, the full‑population analysis did not reach statistical significance, but AriBio announced it will meet with the FDA to decide if the data support approval.
If approved, low‑dose Mvix would be the first oral pill in the United States designed to modify Alzheimer’s progression, according to neurologist Sharon Sha, who led the trial. She called the finding “huge” and “very exciting.”
Sha presented the results Monday at the Clinical Trials on Alzheimer’s Disease conference. She emphasized that a disease‑modifying oral therapy with minimal side effects would be a major advance.
Reported side effects included diarrhea, dizziness, falls and fainting. The safety profile was deemed manageable in the trial.
AriBio has been testing the Viagra‑like drug since late 2022 at a daily 30‑mg dose, roughly one‑third of the standard 100‑mg erectile dysfunction amount. This low dose was chosen to minimize cardiovascular risk while preserving efficacy.
Richard Oakley, associate director of research at Alzheimer’s Society in the United Kingdom, said the results could reshape Alzheimer’s treatment. He highlighted the novel mechanism of relaxing blood vessels to increase cerebral blood flow and the convenience of a once‑daily tablet.
